Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development ProgramPRNewsWire • 10/19/21
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021PRNewsWire • 09/20/21
Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone TechnologySeeking Alpha • 09/16/21
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson'sPRNewsWire • 08/04/21
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor FunctionPRNewsWire • 07/15/21
Alterity Therapeutics shares rise as its new US patent supports bid to find treatment for Alzheimer's and Parkinson'sProactive Investors • 07/01/21
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson'sPRNewsWire • 07/01/21
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical TrialPRNewsWire • 06/23/21
Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative DisorderBenzinga • 04/21/21
Alterity to present at the 7th International Congress of Multiple System AtrophyPRNewsWire • 02/26/21
Alterity Therapeutics Ltd (ATHE) CEO David Stamler on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/26/21
Alterity Therapeutics stock more than doubles on massive volume after new patent announcementMarket Watch • 11/16/20
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseasesPRNewsWire • 11/16/20